{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42","upperLimit":"80","value":"58"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"description":"OS was defined as the time from registration to death due to any cause. Patients who were alive were censored at date of last follow-up. The overall survival at 3 years (a percentage) is reported below.","dispersionType":"95% Confidence Interval","groups":[{"description":"Intervention: Drug: lenalidomide 10 mg orally days 1-21 every 28 days until progression\n\nIntervention: Drug: melphalan 5mg/m\\^2 orally days 1-4 every 28 days until progression\n\nIntervention: Drug: prednisone 60mg/m\\^2, orally days 1-4 every 28 days until progression","id":"OG000","title":"Treatment (Lenalidomide, Melphalan, Prednisone)"}],"paramType":"NUMBER","populationDescription":"Phase 2 patients.","reportingStatus":"POSTED","timeFrame":"registration to death (up to 3 years)","title":"Overall Survival (OS) at 3 Years","type":"SECONDARY","unitOfMeasure":"percentage of patients"}